Back to top
more

Haemonetics (HAE)

(Delayed Data from NYSE)

$91.95 USD

91.95
548,324

+0.45 (0.49%)

Updated Apr 30, 2024 04:00 PM ET

After-Market: $92.05 +0.10 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (147 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why Investors Should Retain Bruker (BRKR) Stock Now

by Zacks Equity Research

Investors are optimistic about Bruker (BRKR) on solid prospects of BSI Nano group and raised guidance.

IDEXX (IDXX) Enhances Fecal Dx Antigen Testing Platform

by Zacks Equity Research

IDEXX's (IDXX) Fecal Dx antigen testing detects the most prevalent and clinically relevant intestinal parasites in dogs and cats.

Quest Diagnostics (DGX) Inks New Deal With Ultima Genomics

by Zacks Equity Research

Quest Diagnostics' (DGX) new partnership is likely to leverage its oncology expertise and national scale.

Here's Why You Should Buy Align Technology (ALGN) Stock Now

by Zacks Equity Research

Investors remain optimistic about Align Technology (ALGN) due to the progress in the Invisalign portfolio and highly favorable solvency.

Here's Why You Should Retain Charles River (CRL) Stock Now

by Zacks Equity Research

Investors are optimistic about Charles River (CRL) owing to growth in the RMS and DSA segments and stable solvency position.

Here's Why Haemonetics (HAE) is a Strong Growth Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

QIAGEN (QGEN) Wins FDA Clearance for NeuMoDx CT/NG Assay

by Zacks Equity Research

QIAGEN (QGEN) receives FDA clearance for the NeuMoDx CT/NG Assay for use on both NeuMoDx 96 and 288 versions of the integrated PCR-based clinical molecular testing system.

LabCorp (LH) to Expand Clinical Trails Access With New Pact

by Zacks Equity Research

LabCorp (LH) and Hawthorne Effect hope to enhance decentralized clinical trials by merging existing services and developing fresh, unique service offers.

Medtronic's (MDT) Percept RC DBS System Secures FDA Approval

by Zacks Equity Research

Medtronic's (MDT) latest innovation joins the Percept family, the first and only DBS system with sensing, directionality and advanced programming.

Neogen's (NEOG) Q2 Earnings Miss Estimates, 2024 View Down

by Zacks Equity Research

Neogen's (NEOG) Q2 revenues decline year over year due to lower Animal Safety business.

Cardinal Health (CAH) Streamlines Operation With New Structure

by Zacks Equity Research

Cardinal Health's (CAH) new reporting structure is likely to streamline operations, providing better visibility of growth areas. At-home solutions and OptiFreight Logistics are possibly the key value creators.

Here's Why Investors Should Retain Integra (IART) Stock Now

by Zacks Equity Research

Investors remain optimistic about Integra (IART) due to the positive outlook for its CSS segment.

Medtronic (MDT) Wins CE Mark for MiniMed 780G With Simplera Sync

by Zacks Equity Research

Medtronic (MDT) secures the CE Mark for the MiniMed 780G system with the disposable, all-in-one Simplera Sync CGM.

Quest Diagnostics (DGX) to Boost Lab Services With New Buyout

by Zacks Equity Research

Quest Diagnostics' (DGX) recent acquisition seeks to increase accessibility to cutting-edge, high-caliber and reasonably priced laboratory services.

Here's Why You Should Retain Omnicell (OMCL) Stock Now

by Zacks Equity Research

Investors are optimistic about Omnicell (OMCL) owing to its strong Pharmacy model and geographical expansion.

Here's Why You Should Retain National Vision (EYE) Stock Now

by Zacks Equity Research

Investors are optimistic about National Vision's (EYE) stock, banking on strong solvency and promising future strategies.

Tandem Diabetes (TNDM) and Abbott Debut New Integrated Offering

by Zacks Equity Research

Tandem Diabetes' (TNDM) t:slim X2 is the first AID system to be integrated with Abbott's Freestyle Libre 2 Plus sensor.

Chemed (CHE) Roto-Rooter Growth Continues, Macro Issues Hurt

by Zacks Equity Research

Within the Hospice segment, Chemed (CHE) is well poised to register growth driven by the growing aging population.

Asensus Surgical (ASXC) Completes Surgeon Lab for LUNA

by Zacks Equity Research

Asensus Surgical's (ASXC) latest Surgeon Lab helps it move closer to a finalized LUNA product.

Indrajit Bandyopadhyay headshot

4 Medical Product Stocks to Buy Amid Industry Challenges

by Indrajit Bandyopadhyay

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. PHG, NEOG, HAE and PBH are well-poised to gain from the favorable factors.

Boston Scientific (BSX) Rides on Global Growth Amid Macro Woes

by Zacks Equity Research

Within APAC, Boston Scientific (BSX) is registering strong growth in Japan and China.

Bruker's (BRKR) New Deal Widens Biopharma PAT Product Portfolio

by Zacks Equity Research

Bruker (BRKR) announces the acquisition of Tornado Spectral Systems Inc., a global provider of chemical analysis & measurement systems for Raman spectroscopy.

Alcon (ALC) Business Hurt by Macroeconomic Woes, Competition

by Zacks Equity Research

In the surgical business, Alcon (ALC) faces a mix of competitors, ranging from large manufacturers with multiple business lines to small manufacturers.

Bruker (BRKR) Expands Materials Science Research via New Deal

by Zacks Equity Research

Bruker (BRKR) announces the acquisition of the electron microscopy company Nion.

Here's Why Investors Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

Investors continue to remain optimistic about STERIS (STE) due to the prospects of the healthcare business.